Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 (0) 1494 818026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Recruitment Consultant
laura@zenopa.com
+44 (0) 1494 818026

Testimonials
I cannot recommend Zenopa highly enough. I found Zenopa to be organised, informed, and friendly. If they didn't have the information or answers to my questions they would get it for me.
Louise, 2012

Roche requested by NICE to provide further Zelboraf data

13 August 2012 11:37 in Pharmaceutical Company Product News


Roche has been requested to provide additional clinical data on its skin cancer therapy Zelboraf to support a potential recommendation of the drug by the National Institute for Health and Clinical Excellence (NICE).

The UK regulator has asked the company to make further information available that demonstrates the benefits of Zelboraf for the treatment of unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma.

Key to this process will be Roche's ability to prove that the drug is a cost-effective means of treating this form of cancer, and offers enough long-term benefits to be worth funding via the NHS.

Professor Carole Longson, health technology evaluation centre director at NICE, said: "We hope that Roche will be able to provide this additional information so that the committee can consider it at its next meeting on the topic."

The successful launch of Zelboraf in Europe earlier this year has been cited by Roche as a business highlight and driver of growth in the first half of 2012, a period that saw the firm experience a three percent year-on-year increase in sales.ADNFCR-8000103-ID-801427319-ADNFCR

Other news stories from 13/08/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd